ScholarIQanswers from OpenAlex
Sendai Kousei Hospital
InstitutionResearch output, impact & collaborations
Sendai Kousei Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about Sendai Kousei Hospital?
ScholarIQrecord summary
Sendai Kousei Hospital is a research organisation in Sendai, JP. OpenAlex records 2,301 works and 73,089 citations for it. 595 researchers list it as their most recent affiliation.
How many works does Sendai Kousei Hospital have?
ScholarIQindexed works
Sendai Kousei Hospital has 2,301 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sendai Kousei Hospital have?
ScholarIQcitation count
Sendai Kousei Hospital has 73,089 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Sendai Kousei Hospital?
ScholarIQresearcher count
Sendai Kousei Hospital has 595 researchers in the ScholarIQ index.
What is the average h-index at Sendai Kousei Hospital?
ScholarIQavg h-index
Sendai Kousei Hospital has an average h-index of 50 in OpenAlex.
What is the ROR of Sendai Kousei Hospital?
ScholarIQror
The ROR for Sendai Kousei Hospital is on the source record.
What is the OpenAlex record for Sendai Kousei Hospital?
ScholarIQopenalex
The OpenAlex for Sendai Kousei Hospital is on the source record.
Who are the most-cited researchers behind Sendai Kousei Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on Sendai Kousei Hospital?
ScholarIQmost cited works
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz‐Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Bárbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp, Jerónimo Rafael Rodríguez‐Cid, Jonathan Wilson, Shunichi Sugawara, Terufumi Kato, Ki Hyeong Lee, Ying Cheng, Silvia Novello, Balázs Halmos, Xiaodong Li, Gregory M. Lubiniecki, Bilal Piperdi, Dariusz M. Kowalski
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, А. Л. Акопов, Alex Martínez‐Martí, Hirotsugu Kenmotsu, Yuh‐Min Chen, Antonio Chella, Shunichi Sugawara, David Voong, Fan Wu, Jing Yi, Yu Deng, Mark L. McCleland, Elizabeth Bennett, Barbara J. Gitlitz, Heather A. Wakelee
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
David Planchard, Pasi A. Jänne, Ying Cheng, James Chih‐Hsin Yang, Noriko Yanagitani, Sang‐We Kim, Shunichi Sugawara, Yan Yu, Yun Fan, Sarayut Lucien Geater, К. К. Лактионов, Chee Khoon Lee, Natalia Valdiviezo, Samreen Ahmed, Jean-Marc Maurel, Igor Andrašina, Jonathan W. Goldman, Dana Ghiorghiu, Yuri Rukazenkov, Alex Todd, Kunihiko Kobayashi
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
Silvia Novello, Dariusz M. Kowalski, Alexander Luft, Mahmut Gümüş, David Vicente, Julien Mazières, Jerónimo Rafael Rodríguez‐Cid, Ali Tafreshi, Ying Cheng, Ki Hyeong Lee, Alexander Golf, Shunichi Sugawara, Andrew Robinson, Balázs Halmos, Erin Jensen, Paul Schwarzenberger, M. Catherine Pietanza, Luis Paz‐Ares
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
Bairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash, Patrick M. Forde, Josephine Feliciano, Kristen A. Marrone, David S. Ettinger, Christine L. Hann, Julie R. Brahmer, Biagio Ricciuti, Dwight H. Owen, Yukihiro Toi, Paul R. Walker, Gregory A. Otterson, Sandip H. Patel, Shunichi Sugawara, Jarushka Naidoo
How much of the research on Sendai Kousei Hospital is open access?
ScholarIQopen access share
71%OPEN ACCESS